Skip to content

Clinical study on the efficacy and safety of rotatable bi-channel en bloc resection of bladder tumor in the treatment of non-muscle-invasive bladder cancer

Clinical study on the efficacy and safety of rotatable bi-channel en bloc resection of bladder tumor in the treatment of non-muscle-invasive bladder cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085611
Enrollment
Unknown
Registered
2024-06-13
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer

Interventions

Phase 1: Rotatable bi-channel bladder tumor en bloc resection (RBC-ERBT) :Rotatable bi-channel bladder tumor en bloc resection (RBC-ERBT)
Phase 2: Rotatable bi-channel bladder tumor en bloc resection (RBC-ERBT) :Rotatable bi-channel bladder tumor en bloc resection (RBC-ERBT)
Phase 2: ERBT:Traditional en bloc resection of bladder tumor (ERBT)

Sponsors

The Second Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Male or female, aged 18 or above. Diagnosed with non-muscle-invasive bladder tumor by preoperative imaging or cystoscopy. No more than 4 lesions. The maximum diameter of a single lesion does not exceed 3 cm. No contraindications to surgery found upon preoperative examination. ECOG score of less than 2. Volunteers who are willing to participate in this study, have signed the informed consent form, and are willing to accept follow-up.

Exclusion criteria

Exclusion criteria: Urethral stricture, making it impossible to introduce the ERBT or RBC-ERBT device transurethrally. Presence of other non-curative malignant tumors. Acute urinary tract infection. Concurrent severe cardiopulmonary dysfunction or coagulation disorder, with inability to tolerate anesthesia or surgery. Poor compliance, unable to cooperate with follow-up treatment.

Design outcomes

Primary

MeasureTime frame
Surgical success rate;Technical success rate;Overall survival (OS);Progression-free survival (PFS);

Secondary

MeasureTime frame
Detrusor Muscle Detection Rate in Specimens;Operation time;Lesion resection time;Secondary resection rate;Postoperative tumor recurrence rate at various time points, including 3 months, 1 year, 2 years, 3 years, and 5 years postoperatively;Postoperative reoperation rate, including 3 months, 1 year, 2 years, 3 years, and 5 years postoperatively;Postoperative survival rate at various time points, including 3 months, 1 year, 2 years, 3 years, and 5 years postoperatively;Incidence of bladder perforation;Incidence of obturator reflex;Incidence of bleeding;Incidence of postoperative complications;Postoperative bladder irrigation time;Duration of indwelling catheter;Postoperative hospital stay time;

Countries

China

Contacts

Public ContactBoxin XUE

The Second Affiliated Hospital of Soochow University

boxin_xue@126.com+86 159 6224 2889

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026